[go: up one dir, main page]

EP3976018B1 - Composition pour utilisation dans le traitement de la fièvre aphteuse, de l'orf, du picornavirus, du parapoxvirus et d'une maladie pathogène provoquant des lésions de la vérole - Google Patents

Composition pour utilisation dans le traitement de la fièvre aphteuse, de l'orf, du picornavirus, du parapoxvirus et d'une maladie pathogène provoquant des lésions de la vérole Download PDF

Info

Publication number
EP3976018B1
EP3976018B1 EP20814805.6A EP20814805A EP3976018B1 EP 3976018 B1 EP3976018 B1 EP 3976018B1 EP 20814805 A EP20814805 A EP 20814805A EP 3976018 B1 EP3976018 B1 EP 3976018B1
Authority
EP
European Patent Office
Prior art keywords
composition
cetrimide
optionally
lignocaine
tetracaine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP20814805.6A
Other languages
German (de)
English (en)
Other versions
EP3976018A1 (fr
EP3976018A4 (fr
Inventor
Charles Robert Olsson
Meredith Sheil
Allan Giffard
Peter Windsor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Animal Ethics Pty Ltd
Original Assignee
Animal Ethics Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019901837A external-priority patent/AU2019901837A0/en
Application filed by Animal Ethics Pty Ltd filed Critical Animal Ethics Pty Ltd
Publication of EP3976018A1 publication Critical patent/EP3976018A1/fr
Publication of EP3976018A4 publication Critical patent/EP3976018A4/fr
Application granted granted Critical
Publication of EP3976018B1 publication Critical patent/EP3976018B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • This invention relates to a topical composition for use in the treatment of a pathogenic disease caused by an acid-labile pathogen selected from foot and mouth disease (FMD), scabby mouth (Orf), Picornavirus, Parapoxvirus, and a pathogenic disease causing pox lesions.
  • the invention also relates to a topical composition for use in the treatment of a diseased area of a subject caused by or aggravated by an acid-labile pathogen selected from the group consisting of foot and mouth disease (FMD), scabby mouth (Orf), Picornavirus, Parapoxvirus, and a pathogenic disease causing pox lesions.
  • Foot and mouth disease also known as hoof and mouth disease (HMD)
  • HMD hoof and mouth disease
  • a highly contagious degenerative viral disease of cloven-hoofed animals such as cattle, buffalo, sheep, swine, goats, antelope, deer and bison. It is caused by a Picornavirus, and its symptoms include fever, loss of appetite and weight, blistering or boils on mucous membranes, particularly those of the mouth, feet and udder, animals walking in short tripping steps, lameness (hoof disease), and death.
  • Infection occurs when the virus is taken into a cell of the animal. The cell then manufactures copies of the virus and eventually bursts, releasing thousands of virus particles. Discharge from blisters on the skin, cavity of the mouth and fissures of the hoof is heavily infected with the virus. The disease is readily transmitted by contact or as an aerosol.
  • the disease is most prevalent in Asia, Africa, and South America. Infected animals are usually quarantined and slaughtered together with healthy ones so as to limit contagion. The entire farm is then usually subjected to thorough disinfection.
  • Scabby mouth also known as contagious pustular dermatitis, contagious ecthyma and orf, is a viral disease of goats and sheep. It is caused by a Parapoxvirus, and its symptoms include scabs and pustules, usually around the mouth and face of affected animals. Most commonly, raised scabs with a red ulcerated area underneath the scab occur around the lips, muzzle and nostril. Less commonly, raised scabs and ulcerated areas occur around the eyes, feet, lower leg, anus, vulva, udder, scrotum and pizzle. In severe cases, infected animal may stop eating, animals may become lame and animals with udder lesions may develop mastitis.
  • Abrasions in the skin enable virus to infect. Infection may also occur upon prolonged wetting of the feet.
  • the disease can be transmitted by contact from sheep to sheep. More commonly, scabs shed from infected sheep spread the disease.
  • Hoof rot/footrot is a catch-all term for a fungal or bacterial infection in the hoof of an animal, such as sheep, goats, cattle, horses and deer.
  • Footrot is caused by a combination of the bacteria Fusobacterium necrophorum and Dichelobacter nodosus (more common in sheep), and Bacteroides melaninogenicus (more common in cattle). Its symptoms include a foul-smelling necrotic lesion of the interdigital skin, swelling, reduced weight gain, decreased milk and wool production, and lameness. It is extremely painful and contagious.
  • Irritation of the interdigital area provides entry of the bacteria for infection.
  • the disease is transmitted primarily from foot to foot via moist pastures, laneways and muddy yards.
  • Footrot is treated by foot bathing, hoof trimming, use of antibiotics and vaccination.
  • the product Tri-Solfen TM (Animal Ethics Pty Ltd) is a local anaesthetic and antiseptic gel spray for use on animals to provide pain relief following animal husbandry procedures such as mulesing, tail docking and castration.
  • the product contains two topical local anaesthetics, being fast-acting lignocaine for immediate pain relief and long-acting bupivacaine for prolonged pain relief.
  • the product's gel base adheres well to open wounds and acts as a barrier to environmental stimuli to improve wound healing.
  • the Tri-Solfen TM product contains adrenalin, to both localise the anaesthetic effect and prevent or minimize systemic absorption, and is of acidic pH. See US Patent Nos. 8,960,128 , 8,822,416 and 9,592,318 (Animal Ethics Pty Ltd ).
  • the present inventors have made a surprising discovery that the Tri-Solfen TM product is particularly effective in treating and controlling foot and mouth disease (FMD) in cattle when applied to a diseased area of the animal.
  • FMD foot and mouth disease
  • the gel-based product might alleviate pain caused by the virus when applied to FMD blistering and boils
  • animals treated with the Tri-Solfen TM product would show markedly hastened healing of their lesions as well as rapidly regain their appetite, gain weight, overcome lameness and survive the disease.
  • an anaesthetic agent could function as an acidic biocidal agent, yet any pain or discomfort caused by the acidic nature of the agent/composition was quickly countered by the fast-acting anaesthetic agent itself.
  • the inventors Based on the findings in cattle with FMD, the inventors have identified the potential to treat other infectious or inflammatory disease caused by a pathogen that results in epithelial or mucosal inflammation, ulceration, sloughing, peeling, excoriation or lesions such as vesicles or blisters that may rupture and form ulcers.
  • Tri-Solfen TM product and like products can be used to treat and control other foot or mouth-type pathogenic diseases, including scabby mouth and hoof rot/footrot/foot abscess.
  • Tri-Solfen TM product and like products could be used to treat and control other bacterial, viral or fungal pathogens, particularly acid-labile pathogens that result in epithelial lesions or ulcerations of the skin or mucous membranes such as Herpesvirus lesions including shingles, cold-sores and genital herpes, and diseases caused by Rhinovirus and Horse Equine Rhinitis A virus (ERAV), Candida such as oral candidiasis, and Tinea.
  • EAV Rhinovirus and Horse Equine Rhinitis A virus
  • Candida such as oral candidiasis, and Tinea.
  • Tri-Solfen TM product and like products could be used to treat and control infestational pathogens such as Lucilia cuprina blowfly larvae.
  • Flystrike lesions are very painful, being caused by the blowfly larvae. Larvae are killed by 0.5% hydrochloric acid. Applying acidic treatment however is likely to be painful. Therefore, a product like Tri-Solfen TM may inactivate larvae while also preventing or treating pain. Flystrike lesions may occur as examples in the breech, perineum, tail, poll pizzle or body of sheep.
  • a topical composition for use in the treatment of a pathogenic disease caused by an acid-labile pathogen selected from foot and mouth disease (FMD), scabby mouth (Orf), Picornavirus, Parapoxvirus, and a pathogenic disease causing pox lesions characterised in that:
  • a topical composition for use in the treatment of a diseased area of a subject caused by or aggravated by an acid-labile pathogen selected from the group consisting of foot and mouth disease (FMD), scabby mouth (Orf), Picornavirus, Parapoxvirus, and a pathogenic disease causing pox lesions, characterised in that: the composition has an acidic pH;
  • FMD foot and mouth disease
  • Orf scabby mouth
  • Picornavirus Picornavirus
  • Parapoxvirus Parapoxvirus
  • a pathogenic disease causing pox lesions characterised in that: the composition has an acidic pH;
  • the pathogenic disease is preferably scabby mouth (Orf) or foot and mouth disease (FMD).
  • the composition or medicament has both pain-relieving and biocidal properties. In each of the aspects, the composition or medicament has rapid pain-relieving properties.
  • the diseased area is the skin or mucous membrane of the subject.
  • the diseased area corresponds to epithelial or mucosal denuding, inflammation, excoriation, ulceration, sloughing, peeling or lesions such as pustules, pox lesions, eruptions, vesicles or blisters that may rupture and form ulcers.
  • the diseased area corresponds to significant epithelial or mucosal denuding, inflammation, excoriation, ulceration, sloughing, peeling or lesions such as pustules, pox lesions, eruptions, vesicles or blisters that may rupture and form ulcers, as opposed to minor epithelial or mucosal denuding, inflammation, excoriation, ulceration, sloughing, peeling or lesions such as pustules, pox lesions, eruptions, vesicles or blisters that may rupture and form ulcers. That is, for example, the composition is used on significant pathogenic ulcerative lesions, as opposed to minor pathogenic ulcers or skin excoriation.
  • the diseased area corresponds to a mouth and/or nasal area of the subject. In some embodiments the diseased area corresponds to the genital and/or anal area of a subject. In some embodiments the diseased area corresponds to a hand, arm, foot, hoof or leg of the subject. In some embodiments the diseased area corresponds to a face or thorax (including abdomen and back) of a subject. In some embodiments the diseased area corresponds to perineum, armpits, under folds of the breasts, in creases or folds of skin on the abdomen etc of a subject. In some embodiments the diseased area corresponds to feet, scalp, skin, or skin folds or creases of a subject. In some embodiments the diseased area corresponds to lesions in the breech, perineum, tail, poll pizzle or body of a subject.
  • composition can be of any suitable form.
  • the composition can be, for example, in the form of a liquid, ointment, gel, lotion, cream, crème, emulsion, paste, film or suspension.
  • the composition can include one or more of the following types of ingredients: adhesive; aqueous or oily diluent; carrier; excipient; base; buffer; pH adjuster; bittering agent (i.e. foul-tasting agent); suspending agent; thickening agent; gelling agent; viscosity increasing agent; emulsifier; emollient; humectant; stabilising agent; dispersing agent/dispersant; solubiliser; skin conditioning agent; skin protectant; skin penetration enhancer; fragrance; preservative; sunscreen agent; surfactant; textural modifier; colourant; propellant; refrigerant; and, waterproofing agent.
  • Suitable oily or aqueous bases, carriers, diluents and excipients are inert and physiologically acceptable and include, for example: bacteriostatic saline (saline containing benzyl alcohol), cetomacrogol, cetyl alcohol, glycerine, lanolin, petrolatum based creams, gels, hydrogels, saline, short chain alcohols and glycols (e.g. ethyl alcohol and propylene glycol), and water.
  • Either water in oil or oil in water emulsions can be used.
  • suitable surfactants and emulsifying agents include: non-ionic ethoxylated and non-ethoxylated surfactants, abietic acid, almond oil PEG, beeswax, butylglucoside caprate, C 18 -C 36 acid glycol ester, C 9 -C 15 alkyl phosphate, caprylic/capric triglyceride PEG-4 esters, cetomacrogol, ceteareth-7, cetereth-20, cetyl phosphate, cetyl stearyl alcohol, corn oil PEG esters, DEA-cetyl phosphate, dextrin laurate, dilaureth-7 citrate, dimyristyl phosphate, glycereth-17 cocoate, glyceryl erucate, glycerol, glyceryl laurate, G.M.S.
  • PEG esters isosteareth-11 carboxylic acid, lecithin, lysolecithin, nonoxynol-9, octyldodeceth-20, palm glyceride, PEG diisostearate, PEG stearamine, poloxamines, polyglyceryls, potassium linoleate, PPGs, raffinose myristate, sodium caproyl lactylate, sodium caprylate, sodium cocoate, sodium isostearate, sodium tocopheryl phosphate, steareths, TEA-C 12 -C 13 pareth-3 sulfate, tri-C 12 -C 15 pareth-6 phosphate, and trideceths.
  • the composition can comprise one or more types of preservative.
  • a suitable preservative for example, can be: benzalkonium chloride, benzoic acid, benzothonium chloride, benzyl alcohol, 2-bromo-2-nitropropane-1,3-diol, bronopol, butylated hydroxyanisole, butylated hydroxytoluene, butyl paraben, chlorophene, chlorphenesin, diazolidinyl urea, DMDM hydantoin, ethyl paraben, formaldehyde-releasing preservative, hydroquinone, iodopropynyl butylcarbamate, imidazolidinyl urea, methyldibromo glutaronitrile, methylhydroquinone, methylisothiazolinone, methyl paraben, nitrosamines, o-cymen-5-ol, phenoxyethanol, propyl paraben
  • the composition can include a colourant so that its application can be verified visually.
  • the colourant can be a pigment and/or dye. Suitable colourants include, for example, common food dyes or the ORCODERM ® , ORCOBRITE ® and ORCOFUR ® lines of pigments and dyes sold by the Organic Dyestuffs Corporation.
  • the colourant is non-toxic and will not permanently stain the skin or animal hide or surrounding hair, fur or wool.
  • a skin conditioning agent improves dry or damaged skin.
  • agents include: acetyl cysteine, N-acetyl dihydrosphingosine, acrylates/behenyl acrylate/dimethicone acrylate copolymer, adenosine, adenosine cyclic phosphate, adensosine phosphate, adenosine triphosphate, alanine, albumen, algae extract, allantoin and derivatives, aloe barbadensis extracts, aluminum PCA, amyloglucosidase, arbutin, arginine, azulene, bromelain, buttermilk powder, butylene glycol, caffeine, calcium gluconate, capsaicin, carbocysteine, carnosine, beta-carotene, casein, catalase, cephalins, ceramides, chamomilla recutita (matricaria) flower extract, chole
  • the composition can include a skin penetration enhancer for enhancing the penetration of active ingredients.
  • a skin penetration enhancer for enhancing the penetration of active ingredients.
  • Any suitable type of enhancer can be used.
  • suitable enhancers may include solvents, detergents or low carbon alcohols such as dimethylsulfoxide, oleyl alcohol, propylene glycol, methyl pyrrolidone and dodecylazyl cycloheptan 2-one.
  • the composition can comprise one or more of the following adhesives, thickening agents, gelling agents and/or viscosity increasing agents: acrylamides copolymer, agarose, amylopectin, calcium alginate, calcium carboxymethyl cellulose, carbomer, carboxymethyl chitin, castor oil derivatives, cellulose gum, cellulosic preparation, cetyl alcohol, cetostearyl alcohol, dextrin, gelatin, hydroxy cellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxpropyl starch, inert sugar, magnesium alginate, methylcellulose, microcrystalline cellulose, pectin, PEG's, polyacrylic acid, polymethacrylic acid, polyvinyl alcohol, quaternium ammonium compound of bentonite or zinc stearate, sorbitol, PPG's, sodium acrylates copolymer, sodium carrageenan, xanthum gum, and yeast beta-glucan.
  • the composition can comprise an insecticide or insect repellent to stop insect infestation.
  • Any suitable type of insecticide or insect repellent can be used.
  • suitable insecticides include: trichlorfon, triflumeron, fenthion, bendiocarb, cyromazine, dislubenzuron, dicyclanil, fluazuron, amitraz, deltamethrin, cypermethrin, chlorfenbinphos, flumethrin, ivermectin, abermectin, avermectin, doramectin, moxidectin, zeti-cypermethrin, diazinon, spinosad, imidacloprid, nitenpyran, pyriproxysen, sipronil, cythioate, lufenuron, selamectin, milbemycin oxime, chlorpyrifos, coumaphos, propetamphos,
  • the composition can be applied to the subject (or diseased area of the subject) in any suitable form.
  • the composition can be applied in a liquid form or other free-flowing form.
  • the composition can be applied as a spray-on liquid or spray-on gel so as to minimise pain related to touching a subject, minimise the risk of infection from skin contamination and so that the diseased area need not be disturbed more than necessary.
  • the composition can be applied as a gel by hand, or squeezed from a tube.
  • the composition is adhesive or sticky or tenacious.
  • the composition can be, for example, in the form of an ointment, gel, foam, lotion, crème, cream, emulsion, paste, solution or suspension, or may set and /or form a physical barrier, 'skin', coating or film.
  • the composition can be, for example, in the form of an adhesive/sticky/tenacious ointment, gel, foam, lotion, crème, cream, emulsion, paste, solution or suspension, or may set and /or form an adhesive physical barrier, 'skin', coating or film.
  • the composition may form an adhesive coat or coating, layer, barrier, skin or film. That is, the composition can be adhesive.
  • the composition may foam and spread over those wet surfaces, or otherwise coat and spread over those wet surfaces.
  • the composition can be in a sustained-release form, whereby one or more actives of the composition are slowly released to provide a therapeutic effect over an extended period of time (eg. biocidal activity, pain relief, antiviral activity).
  • actives of the composition eg. biocidal activity, pain relief, antiviral activity.
  • composition can be incorporated into a bandage, plaster, dressing, wipe or tissue.
  • the composition can be applied as a metered dose.
  • composition can form or can be in the form of an adhesive gel after being applied to the subject.
  • composition can form or can be in the form of a foam after being applied to the subject.
  • the composition can be both adhesive/sticky in a relatively dry diseased area and/or form a foam in a relatively wet diseased area.
  • the composition can comprise a hydrophilic or hydroalcoholic gelling agent.
  • the composition can comprise about 1 to 20 g per litre of at least one type of gum or cellulosic preparation, including all about 0.1 g increments between 1 and 20, including 1.1, 1.2 etc.
  • the composition can comprise a polyhydric alcohol in combination with a cellulosic preparation; for example, hydroxy cellulose (eg. hydroxyethyl cellulose, ethylhydroxy cellulose) in combination with non-crystallising liquid sorbitol.
  • the composition can comprise about 5 mg/ml hydroxy cellulose (eg. hydroxyethyl cellulose) in combination with about 100 mg/ml non-crystallising liquid sorbitol (70%).
  • the composition is in the form of a liquid prior to having been applied to a subject.
  • the composition forms, or is in the form of, a sticky, viscous, adhesive gel when applied to a subject.
  • the composition is in the form of a spray-on gel that can coat the diseased area of the subject and can maximise delivery of actives to the diseased area of the subject, preferably by way of staying moist and viscous (i.e. "sticky").
  • the composition forms, or is in the form of, a foam when applied to a subject.
  • the composition is in the form of a foam that can coat the diseased area of the subject and can maximise delivery of actives to the diseased area of the subject.
  • the composition as a foam, can spread throughout the diseased area.
  • the composition forms an effective long-lasting barrier over the diseased area.
  • long-lasting barrier is to be understood as meaning a barrier/seal that is substantially capable of remaining intact over a diseased area for hours, days, a week or even weeks, or until the wound has naturally sealed or the pain has otherwise abated by way of the natural healing process - eg. about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 hours, or about one, two, three, four, five, six or seven days, or one, two, three, four or more weeks.
  • the barrier preferably aids in the healing process, presumably by minimising or preventing water loss from the diseased area and by acting as a barrier against microbial contamination.
  • the composition is in the form of a liquid that thickens to an adhesive gel when reacting with physiological fluids of the diseased area of the subject.
  • the composition can provide prolonged pain relief, including pain relief for about 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 hours, or about one, two, three, four, five, six or seven days, or one, two, three, four or more weeks, or until the wound has naturally sealed or the pain has otherwise abated by way of the natural healing process.
  • the composition can provide prolonged pain relief, including pain relief for about 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 hours, or about one, two, three, four, five, six or seven days, or one, two, three, four or more weeks.
  • the composition can provide prolonged release of a biocidal agent or exposure to a biocidal property, including for about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 hours, or about one, two, three, four, five, six or seven days, or one, two, three, four or more weeks.
  • the composition comprises both at least one local anaesthetic agent having a rapid onset of action and at least one local anaesthetic agent having a long duration of action.
  • some local anaesthetic agents can provide both a rapid onset of action and long duration of action, such as amethocaine / tetracaine, so the local anaesthetic agent providing a rapid onset of action and local anaesthetic agent providing a long duration of action can be one and the same.
  • Anaesthetic agents that usually have a rapid onset of action (usually between about 5-10 minutes) include lignocaine, prilocaine, amethocaine / tetracaine and cocaine.
  • Anaesthetic agents that often have a much slower onset of action but a much greater duration of action (usually between about 4-12 hours of anaesthesia) include bupivacaine, ropivacaine, levo-bupivacaine, and amethocaine / tetracaine.
  • Bupivacaine may typically provide up to about 6-12 hours of anaesthesia, depending on the method of administration.
  • anaesthetic agent can be used in the composition but preferably about 0.01-10 weight/volume % of anaesthetic agent is used (as well as all 0.01 increments between 0.01 and 10, eg. 0.01, 0.02 etc).
  • any suitable amount of rapid onset anaesthetic agent can be used in the composition but preferably about 0.01-10 weight/volume % of anaesthetic agent is used (as well as all 0.01 increments between 0.01 and 10). Preferably, about 2-8 weight/volume % anaesthetic agent is used in those situations where a rapid onset of action is required (as well as all 0.01 increments between 2 and 8). More preferably, about 5 % weight/volume anaesthetic agent is used.
  • about 1-10 weight/volume % lignocaine is used (as well as all 0.01 increments between 1 and 10, eg. 0.01, 0.02 etc). In some embodiments, about 2-8 weight/volume % lignocaine is used as the anaesthetic agent in those situations where a rapid onset of action is required (as well as all 0.01 increments between 2 and 8). In some embodiments, about 5 % lignocaine is used.
  • any suitable amount of long duration of action anaesthetic agent can be used in the composition but preferably about 0.01-10 weight/volume % of anaesthetic agent is used (as well as all 0.01 increments between 0.01 and 10). Preferably, about 0.1-5 weight/volume % anaesthetic agent is used in those situations where a long duration of action is required (as well as all 0.01 increments between 0.1 and 5). More preferably, about 0.5 % weight/volume anaesthetic agent is used.
  • the composition can comprise any suitable amount of bupivacaine if lignocaine or other rapid onset anaesthetic agent has an inadequate duration of action.
  • the composition comprises about 0.1-5 weight/volume % bupivacaine (as well as all 0.01 increments between 0.1 and 5), and more preferably about 0.5% bupivacaine.
  • the composition can comprise any suitable amount of tetracaine.
  • the composition comprises about 1-10 weight/volume % tetracaine (as well as all 0.01 increments between 1 and 10).
  • At least one analgesic agent and/or at least one anti-inflammatory agent can be used.
  • suitable analgesic and/or anti-inflammatory agents include: 1-menthol, acetaminophen, alclofenac, aspirin, bendazac, betamethasone, bufexemacpiroxicam, camphor, choline salicylate, clidanac, clofezone, corticosterone, cortisone, dexamethasone, diclofenac, diflunisal, fenbufen, fenoprofen, fentiazac, fludrocortisone, fluocinolone, fluphenamic acid, flurandrenolide, flurbiprofen, glycol salicylate, halcinonide, hydrocortisone, ibuprofen, indomethacin, indoprofen, ketoprofen, meclofenamate sodium, mefenamic acid, medrysone
  • analgesic agents include one or more of the following: acetaminophen, aspirin, salicylic acid, methyl salicylate, choline salicylate, glycol salicylate, 1-menthol, camphor, mefenamic acid, fluphenamic acid, indomethacin, diclofenac, alclofenac, ibuprofen, ketoprofen, pranoprofen, fenoprofen, sulindac, fenbufen, clidanac, flurbiprofen, indoprofen, protizidic acid, fentiazac, tolmetin, tiaprofenic acid, bendazac, bufexemacpiroxicam, phenylbutazone, oxyphenbutazone, clofezone, pentazocine, mepirizole, hydrocortisone, cortisone, dexamethasone, fluocinolone, triamcinolone, medrys
  • NSAIDs non-steroidal anti-inflammatory drug
  • salicylate e.g. aspirin (acetylsalicylic acid), diflunisal (dolobid), salicylic acid and other salicylates, salsalate (disalcid)
  • propionic acid derivative e.g. ibuprofen, dexibuprofen, naproxen, fenoprofen, ketoprofen, dexketoprofen, flurbiprofen, oxaprozin, loxoprofen
  • acetic acid derivative e.g.
  • enolic acid (oxicam) derivative e.g. piroxicam, meloxicam, tenoxicam, droxicam, lornoxicam. isoxicam, phenylbutazone
  • anthranilic acid derivative (fenamate) e.g. mefenamic acid, meclofenamic acid, flufenamic acid, tolfenamic acid
  • selective COX-2 inhibitor e.g.
  • sulfonanilide e.g. nimesulide
  • other e.g. clonixin, licofelone, H-harpagide in Figwort or Devil's Claw
  • meloxicam In some embodiments approximately 0.1% (1mg/ml) meloxicam or other NSAID is used.
  • analgesic or anti-inflammatory agent can be used in the composition but preferably about 0.01-10 weight/volume % of agent is used (as well as all 0.01 increments between 0.01 and 10).
  • the composition can further include a vasoconstrictor to decrease the rate of vascular absorption of the pain relieving agent, so to improve the depth and duration of pain relieving agent, to reduce bleeding from a wound of the subject, as well as to reduce systemic toxicity.
  • the vasoconstrictor can also lower the pH. Any suitable type of vasoconstrictor can be used, including any suitable salt or form thereof. Suitable vasoconstrictors include, for instance, adrenaline (epinephrine), noradrenalin (norepinephrine) and fenylpressin, including any suitable salt or form thereof.
  • the composition includes about 1:1000-1:10,000 vasoconstrictor (as well as all 10 factor increments between 1000 to 10,000), and more preferably 1:2,000 vasoconstrictor.
  • the vasoconstrictor is adrenaline.
  • the composition or medicament can comprise at least one biocidal agent.
  • the composition or medicament can have biocidal properties attributable to any one or more of the following: low pH (below about pH 4.0, but more preferably below about pH 3.0); antiseptic agent; antimicrobial agent; viricidal agent (eg. at least one anaesthetic agent such as lidocaine, preferably in high doses); antifungal agent; antibiotic; and, vaccine antigen specific for the pathogen.
  • low pH below about pH 4.0, but more preferably below about pH 3.0
  • antiseptic agent e.g. at least one anaesthetic agent such as lidocaine, preferably in high doses
  • viricidal agent eg. at least one anaesthetic agent such as lidocaine, preferably in high doses
  • antifungal agent e. at least one anaesthetic agent such as lidocaine, preferably in high doses
  • antibiotic e.g. at least one anaesthetic agent such
  • the composition can include one or more other active ingredients.
  • An active ingredient as defined herein, is a compound that provides benefit to the subject.
  • the active ingredient can be, for instance, an anticoagulant, antiproliferative, cytokine, cytotoxin, growth factor, interferon, haemostatic agent, hormone, lipid, demineralized bone or bone morphogenetic protein, cartilage inducing factor, oligonucleotide, polymer, polysaccharide, polypeptide, protease inhibitor, vitamin, mineral, and, insecticide or insect repellent.
  • the composition can have a pH below about 4.0, which includes a pH of about 3.9, 3.8, 3.7, 3.6, 3.5, 3.4, 3.2, 3.1, 3.0 .2.9, 2.8, 2.7, 2.6, 2.5, 2.4, 2.3, 2.2, 2.1 and 2.0.
  • the composition preferably includes an antiseptic agent to, amongst other things, minimize wound contamination and infection, and act as an anti-viral agent.
  • an antiseptic agent to, amongst other things, minimize wound contamination and infection, and act as an anti-viral agent.
  • Any suitable type of antiseptic agent can be used.
  • Suitable antiseptic agents include cetrimide, povidone-iodine, chlorhexidine, iodine, benzalkonium chloride, benzoic acid, nitrofurazone, benzoyl peroxide, hydrogen peroxide, hexachlorophene, phenol, resorcinol and cetylpyridinium chloride.
  • the subject can be a human.
  • the subject can be an animal.
  • the subject can be any member of the mammalian order Artiodactyla.
  • the subject can be any relevant type of hoofed animal.
  • the subject can be any relevant type of hoofed African animal.
  • Hoofed animals include, for example: cattle, reindeer, giraffe, deer, sheep, moose, camel, hippopotamus, goat, pig, boar, elk, llama, bison, alpaca, okapi, yak, ruminants of the suborder Ruminantia, buffalo, gaur, antelope, gazelle, ox, gnu and suid.
  • the animal is preferably a sheep, horse, cow, goat, pig, deer, antelope, bison or buffalo.
  • composition is capable of coating and adhering to a diseased area of the subject.
  • the composition is capable of controlled and/ or prolonged release of a biocidal agent or exposure to a biocidal property.
  • the composition is capable of providing rapid pain relief.
  • the composition is capable of providing prolonged pain relief.
  • the composition is capable of providing both rapid pain relief and prolonged pain relief.
  • the composition is capable of providing rapid pain relief so as to relief pain caused by an acidic composition.
  • composition is biocompatible and absorbable such that it does not require removal.
  • the composition comprises an adhesive gel base capable of coating and adhering to a diseased area and providing prolonged contact with the diseased area and controlled and/or prolonged release of a biocidal agent or exposure to a biocidal property.
  • the biocidal property is that the composition comprises a pH less than about 3.0. In some embodiments, the biocidal agent is lignocaine. In some embodiments, the biocidal property is that the composition is acidic and can inactivate a pathogenic virus. In some embodiments, the biocidal agent is substantially uniformly dispersed throughout the composition. In some embodiments, the biocidal agent is an antiseptic, such as cetrimide. In some embodiments, the composition comprises a gelling agent or thickener, such as hydroxyethyl cellulose. In some embodiments, the composition comprises a gelling agent or thickener, such as non-crystallising liquid sorbitol (70%).
  • the composition comprises a colourant, such as a dye.
  • the composition comprises a pH less than about 4.0, preferably less than about 3.0.
  • the composition is in the form of a liquid that sets as a sticky viscous gel when exposed to the diseased area.
  • the composition comprises: a liquid gel matrix that contains the following: lidocaine; adrenalin; and cetrimide, and the composition is optionally coloured; or a liquid gel matrix that contains the following: tetracaine; adrenalin; and cetrimide, and the composition is optionally coloured; or a liquid gel matrix that contains the following: lidocaine; bupivacaine; adrenalin; and cetrimide, and the composition is optionally coloured, wherein said composition has a pH lower than about 4.0.
  • composition 1 comprises:
  • lignocaine can be swapped out and tetracaine swapped in at about 1-10%, but preferably about 5% (50mg/ml) ("Composition 2").
  • composition 3 comprises:
  • lignocaine can be swapped out and tetracaine swapped in at about 1-10%, but preferably about 5% (50mg/ml) ("Composition 4").
  • composition 5 comprises:
  • composition 6 comprises: lignocaine, bupivacaine, adrenaline, cetrimide, 2-ethyl hydroxycellulose, sodium metabisulfite, liquid sorbitol (70%), buffer, and, optionally colourant such as a dye.
  • lignocaine can be swapped out and tetracaine swapped in at about 1-10%, but preferably about 5% (50mg/ml) ("Composition 7").
  • composition 8 comprises: amethocaine / tetracaine, adrenaline, cetrimide, 2-ethyl hydroxycellulose, sodium metabisulfite, liquid sorbitol (70%), buffer, and, optionally, colourant such as a dye.
  • composition 9 is as described or substantially as described in US Patent Nos. 8,960,128 , 8,822,416 and 9,592,318 (to Animal Ethics Pty Ltd ).
  • Any suitable dosage and dosage regime can be used. This will depend on, amongst other things, the ingredients/actives/properties of the composition, the size/weight of the subject being treated, the size of the diseased area/lesion area being treated, and the frequency of reapplication of the composition that is required (if any).
  • Suitable dosages can be gleaned, for example, from the Best Mode section of this specification.
  • the entire diseased area of the subject is coated with the composition, eg. hoof and mouth regions, in the case of foot and mouth disease.
  • the amount applied will vary according to the number and size of the diseased areas/lesions.
  • compositions 1 to 9 and similar compositions in some embodiments this will usually amount to application of between about 5ml and 60ml of Composition per subject, including all 0.1 ml values between 5 and 60. However, more or less could be applied.
  • compositions 1 to 9 and similar compositions in some embodiments this will amount to application of between about 6ml and 20ml of Composition per subject, including all 0.1 ml values between 6 and 20. However, more or less could be applied.
  • Foot and mouth-disease is a highly infectious viral disease that affects animals with cloven hooves such as cattle, pigs, sheep, goats and artiodactyl wildlife species.
  • the disease is characterized by fever, salivation and vesicles in the mouth, muzzle, dental pad, tongue, teats and feet.
  • the rupture of the vesicles results in marked painful swelling of the coronary band, depression, innapetence, lameness, recumbency, loss of body condition, severe mastitis and abortions (Radostitis et al. 2000).
  • the global impact of foot and mouth disease is colossal due to the huge numbers of animals affected.
  • the annual impact of FMD in terms of production losses and vaccination alone are estimated as in the region of US$5 billion (Knight-Jones and Rushton 2013).
  • Much of the global FMD burden of production losses falls on the world's poorest communities, particularly those most dependent on livestock in developing countries.
  • the direct losses limit livestock productivity creating a food insecurity and contributing to malnutrition.
  • the FMD virus belongs to the Aphthovirus genus of Picornaviridae family, and its classification has seven serotypes (O, A, Asia 1, C, SAT 1, SAT 2, and SAT 3) and about 80 subtypes (Kahn et al. 2005).
  • the serotypes have a large number of strains that have a spectrum of antigenic characteristics requiring more than one vaccine strain for each serotype (Kahn et al. 2005). There is no cross immunity between serotypes and this presents difficulties to vaccination programs (Radostitis et al. 2000).
  • the disease is highly contagious.
  • the mode of transmission from infected animal to susceptible one is by inhalation, or direct contact with infected lesions or secretions.
  • Exhaled air containing the virus infects susceptible animals via the respiratory or oral route. All body excretions and secretions from infected animal may contain the virus.
  • Transmission to calves is via infected milk and fodder contaminated from contact with infected animals.
  • Other sources of infection include: milk tankers, mechanical animal vectors like horses, cat, dogs, avian species and humans. Pigs are considered 'amplifying hosts'; often infected by contaminated feed derived from infected animals, spreading large volumes of virus that may spread the disease via aerosol to the cattle and other species (Kahn et al. 2005).
  • the virus is known to be highly acid labile. FMD virus does not have an outer membrane and therefore is destroyed rapidly in conditions below pH 5.0 and above pH 11.0. At pH ⁇ 4 it undergoes rapid and complete destruction (Bachrach et al., 1957). Citric acid is commonly used for disinfection of animal housing and surrounding contaminated environments (Sellers et al., 1968).
  • FDM lesions are extremely painful for animals and results in lameness and pain on eating and drinking. Together these result in rapid loss of condition. Ulcers often take weeks to heal and foot lesions may become secondarily infected, compounding morbidity.
  • FMD The conventional method of treating infected animals, where available, mainly involves the use of antibiotics, flunixin meglumine and mild disinfectants (Radostitis et al. 2000).
  • FMD has been managed traditionally by use of natural soda ash solution for washing of the lesions and other communities have applied honey and even finger millet flour to the lesions (Gakuya et al., 2010).
  • Tri-Solfen TM (developed by Animal Ethics Pty Ltd) is a proprietary topical anaesthetic and antiseptic wound-care product that is applied directly to wounds in animals to mitigate pain, bleeding and infection. It contains two local anaesthetics; lidocaine/lignocaine, for rapid onset and bupivacaine, for prolonged duration of local anaesthetic effect, as well as adrenalin, to prevent systemic absorption of local anaesthetic actives, and cetrimide for antiseptic activity.
  • Tri-Solfen TM is registered and widely used in livestock species (sheep and cattle) in Australia and New Zealand to mitigate pain due to wounds from surgical husbandry procedures such as castration, docking and dehorning and mulesing. It is applied directly to wounds using a "no touch” technique as a metered dose "spray and stay” formulation that adheres to the wound, providing a long-lasting coating over the wound to provide prolonged delivery of the actives. Numerous studies have reported significant reductions in pain associated with wounds in sheep, cattle and pigs (Lomax et al., 2008, 2010 and 2013, 2017).
  • Tri-Solfen TM use for pain mitigation was performed during an FMD outbreak in buffalo in Laos in March 2019.
  • Tri-Solfen TM product is a blue coloured liquid gel matrix that contains the following components: lidocaine hydrochloride; bupivacaine hydrochloride; adrenalin; and cetrimide.
  • the Tri-Solfen TM commercial product contains:
  • Tri-Solfen TM product was applied using the "no-touch" metered-dose spray applicator directly to coat ulcerative lesions where-ever present in or around the mouth, nose or on the hooves. Applications were sufficient to coat the wounds without run-off, with total doses between 10-30ml applied per animal.
  • Tri-Solfen TM product The pain-alleviation effects of Tri-Solfen TM product observed in this trial, along with absence of adverse effects, are highly consistent with positive pain relieving effects reported in cattle with wounds from other sources as detailed above.
  • the flow-on effects in buffalo/cattle with FMD have resulted in markedly improved locomotion feeding and recovery, with dramatic potential benefits for health and welfare of cattle/buffalo and communities in FMD outbreaks.
  • Tri-Solfen TM product Direct anti-viral activity of Tri-Solfen TM product is thought to proceed from a unique synergistic combination of factors.
  • FMD virus has high sensitivity to acid environments and is rapidly destroyed at pH ⁇ 4.
  • Tri-Solfen TM product has a pH of 2.7 and thus has direct viricidal activity against FMD virus when applied to exposed lesions where virus is still present.
  • the application of acidic solutions to open wounds and ulcers, such as present in FMD is contraindicated as the acidity may exacerbate pain and be poorly tolerated.
  • the relatively high concentration of lidocaine (5%) applied with adrenalin is known to result in rapid and prolonged wound anaesthesia. This combination therefore, uniquely delivers to the lesion, a long-lasting solution with acidity sufficient to destroy the virus, without causing pain to the animal.
  • lidocaine at concentrations present in Tri-Solfen TM product, should have direct viricidal effects. Although it has not been tested for activity against FMD until now, lidocaine and its pharmaceutically active salts are known to exhibit antiviral activity against Herpes Virus in cell culture and animal model systems at concentrations ranging from 0.5mg/ml (0.05%) to 100mg/ml (10%) (Haines et al., 1986).
  • Cetrimide another active in Tri-Solfen TM product, is a quaternary ammonium antiseptic also with known antiviral activity, however may or may not have activity against FMD virus, as quaternary ammonium compounds are generally considered ineffective against viruses without lipid membranes (such as FMD) (Shirai 2012).
  • the combined effect of the acidic pH, with the antiseptic and antiviral effects of the actives appears to have eradicated the virus from exposed lesions and associated inflammatory secretions, as well as minimising secondary bacterial infection. This, in turn, may not only reduce viral and bacterial load on the animal (and hence hasten healing and recovery) but should also eliminate viral shedding from wounds, and prevent spread of the disease to other animals or the environment via contact with infected lesions or inflammatory secretions from wounds.
  • Such a combination of effects may be anticipated to deliver profound benefits for the well-being of animals, herds and communities affected by FMD outbreaks.
  • the potential to not only reduce animal suffering and speed recovery but also to greatly reduce the extent and severity of outbreaks may have profound health, welfare and economic benefits.
  • Orf is a highly contagious eruptive skin condition of sheep and goats, caused by a Parapoxvirus with a worldwide distribution. It affects mainly lambs and kids, with more serious outbreaks often associated with intensive husbandry, causing significant financial losses to livestock production. It is also a zoonotic disease, affecting mainly people via direct or indirect contact with infected animals. Vaccination remains the preferred option to control the disease. However, currently in Spain and many other countries, no orf vaccine is available. The treatment of this disorder referred to as Contagious Ecthyma and Scabby Mouth, involves standard hygiene practices and management of presumptive secondary infections.
  • Cotton swabs were obtained before treatment (T0) and days 1 (T1), 3 (T2) and 5 (T3) post-treatment, then submitted to direct DNA extraction and real-time PCR quantification (Exopol) or to incubation with primary tissue cultures from ovine skin fibroblasts (OSF) and T-immortalized goat embryonic fibroblasts (TIGEF). Orf quantification was performed by real time PCR on DNA from cultured cells at day 0 and 5 post-treatment. Data were analyzed using the non-parametric Wilcoxon test for paired samples and by T-Student's test for unrelated samples.
  • the inventors have made a surprising discovery that the Tri-Solfen TM gel product is particularly effect in treating and controlling FMD in bovine species when applied to a diseased area of the animal.
  • the inventors postulate that similar compositions having both viricidal and rapidly acting pain-relieving properties can be used to treat and control FMD - especially compositions that are adhesive/sticky in relatively dry diseased areas and/or foam in relatively wet diseased areas.
  • the inventors also postulate that the Tri-Solfen TM product and like products can be used to treat and control other foot or mouth-type pathogenic diseases, including scabby mouth and hoof rot/footrot/foot abscess.
  • Tri-Solfen TM product and like products can be used to treat and control other viral, bacterial or fungal diseases in humans and animals - particularly those that are acid-labile, such as Herpes, Parvovirus, Rhino-virus and Equine rhinitis A virus, and Candida and Tinea.
  • Tri-Solfen TM product and like products can be used to treat and control diseases in humans and animals caused by infestational pathogens, such as those causing flystrike - particularly those that are acid-labile, such as screw worm and blowfly larvae.
  • Treatment of diseased animals or humans could be carried out, largely as described for FMD, by applying the composition/solution topically to all exposed lesions (denuded, excoriated, inflamed, blistered, erupted or ulcerated skin or mucous membranes) in sufficient amount to coat the surface of the lesions.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Anesthesiology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (4)

  1. Composition topique destinée à être utilisée dans le traitement d'une maladie pathogène causée par un agent pathogène acido-labile choisi dans la fièvre aphteuse (FMD), l'ecthyma contagieux (Orf), les picornavirus, les parapoxvirus et une maladie pathogène causant des lésions papuleuses, caractérisée en ce que : la composition a un pH acide ;
    la composition est appliquée à un sujet dans des quantités thérapeutiquement efficaces ; et la composition comprend :
    (a) Composition 1 comprenant :
    environ 100 mg/ml de sorbitol liquide non cristallisant (70 %) ; environ 50,0 mg/ml de chlorhydrate de lignocaïne ;
    environ 5,0 mg/ml de chlorhydrate de bupivacaïne ;
    environ 1,5 mg/ml de métabisulfite de sodium ;
    environ 5,0 mg/ml de cétrimide ;
    environ 45,0 µg/ml de tartrate d'adrénaline ;
    environ 5,0 mg/ml d'hydroxycellulose ; et éventuellement un colorant ;
    (b) Composition 2 dans laquelle la lignocaïne de la Composition 1 est remplacée par de la tétracaïne à raison d'environ 10 mg/ml - 100 mg/ml ;
    (c) Composition 3 comprenant :
    environ 100 mg/ml de sorbitol liquide non cristallisant (70 %) ;
    environ 40,0 mg/ml de chlorhydrate de lignocaïne ;
    environ 1,5 mg/ml de métabisulfite de sodium ;
    environ 5,0 mg/ml de cétrimide ;
    environ 36,0 µg/ml de tartrate d'adrénaline ;
    environ 5,0 mg/ml d'hydroxycellulose ; et éventuellement un colorant ;
    (d) Composition 4 dans laquelle la lignocaïne de la Composition 3 est remplacée par de la tétracaïne à raison d'environ 10 mg/ml - 100 mg/ml ;
    (e) Composition 5 comprenant :
    environ 100,0 mg/ml d'eau purifiée et sorbitol liquide 70 % non cristallisant ;
    environ 50,0 mg/ml (5 %) de chlorhydrate de tétracaïne ;
    environ 1,5 mg/ml de métabisulfite de sodium ;
    environ 5,0 mg/ml de cétrimide ;
    environ 45,0 µg/ml de tartrate d'adrénaline ;
    environ 5,0 mg/ml d'hydroxycellulose ;
    à 1 ml d'eau purifiée ; et éventuellement un colorant (quantité à adapter) ;
    (f) Composition 6 comprenant : lignocaïne, bupivacaïne, adrénaline, cétrimide, 2-hydroxyéthylcellulose, métabisulfite de sodium, sorbitol liquide (70 %), tampon et, éventuellement, colorant ;
    (g) Composition 7 dans laquelle la lignocaïne de la Composition 6 est remplacée par de la tétracaïne à raison d'environ 10 mg/ml - 100 mg/ml ;
    (h) Composition 8 comprenant : améthocaïne / tétracaïne, adrénaline, cétrimide, 2-hydroxyéthylcellulose, métabisulfite de sodium, sorbitol liquide (70 %), tampon et, éventuellement, colorant ;
    (i) Composition 9 comprenant une matrice de gel liquide contenant les éléments suivants :
    lidocaïne ;
    adrénaline ; et
    cétrimide,
    et la composition est éventuellement colorée, dans laquelle ladite composition a un pH inférieur à environ 4,0;
    (j) Composition 10 comprenant une matrice de gel liquide qui contient les éléments suivants : tétracaïne, adrénaline et cétrimide, et la composition est éventuellement colorée, dans laquelle ladite composition a un pH inférieur à environ 4,0; ou
    (k) Composition 11 comprenant une matrice de gel liquide qui contient les éléments suivants : lidocaïne, bupivacaïne, adrénaline et cétrimide, et la composition est éventuellement colorée, dans laquelle ladite composition a un pH inférieur à environ 4,0.
  2. Composition topique destinée à être utilisée dans le traitement d'une zone malade d'un sujet, causée ou aggravée par un agent pathogène acido-labile choisi dans le groupe consistant en fièvre aphteuse (FMD), ecthyma contagieux (Orf), picornavirus, parapoxvirus et une maladie pathogène causant des lésions papuleuses, caractérisée en ce que :
    la composition a un pH acide ;
    la composition est appliquée sur la zone malade ; et
    la composition comprend :
    (a) Composition 1 comprenant :
    environ 100 mg/ml de sorbitol liquide non cristallisant (70 %) ;
    environ 50,0 mg/ml de chlorhydrate de lignocaïne ;
    environ 5,0 mg/ml de chlorhydrate de bupivacaïne ;
    environ 1,5 mg/ml de métabisulfite de sodium ;
    environ 5,0 mg/ml de cétrimide ;
    environ 45,0 µg/ml de tartrate d'adrénaline ;
    environ 5,0 mg/ml d'hydroxycellulose ; et éventuellement un colorant ;
    (b) Composition 2 dans laquelle la lignocaïne de la Composition 1 est remplacée par de la tétracaïne à raison d'environ 10 mg/ml - 100 mg/ml ;
    (c) Composition 3 comprenant :
    environ 100 mg/ml de sorbitol liquide non cristallisant (70 %) ;
    environ 40,0 mg/ml de chlorhydrate de lignocaïne ;
    environ 1,5 mg/ml de métabisulfite de sodium ;
    environ 5,0 mg/ml de cétrimide ;
    environ 36,0 µg/ml de tartrate d'adrénaline ;
    environ 5,0 mg/ml d'hydroxycellulose ; et éventuellement un colorant ;
    (d) Composition 4 dans laquelle la lignocaïne de la Composition 3 est remplacée par de la tétracaïne à raison d'environ 10 mg/ml - 100 mg/ml ;
    (e) Composition 5 comprenant :
    environ 100,0 mg/ml d'eau purifiée et sorbitol liquide 70 % non cristallisant ;
    environ 50,0 mg/ml (5 %) de chlorhydrate de tétracaïne ;
    environ 1,5 mg/ml de métabisulfite de sodium ;
    environ 5,0 mg/ml de cétrimide ;
    environ 45,0 µg/ml de tartrate d'adrénaline ;
    environ 5,0 mg/ml d'hydroxycellulose ;
    à 1 ml d'eau purifiée ; et éventuellement un colorant (quantité à adapter) ;
    (f) Composition 6 comprenant : lignocaïne, bupivacaïne, adrénaline, cétrimide, 2-hydroxyéthylcellulose, métabisulfite de sodium, sorbitol liquide (70 %), tampon et, éventuellement, colorant ;
    (g) Composition 7 dans laquelle la lignocaïne de la Composition 6 est remplacée par de la tétracaïne à raison d'environ 10 mg/ml - 100 mg/ml ;
    (h) Composition 8 comprenant : améthocaïne / tétracaïne, adrénaline, cétrimide, 2-hydroxyéthylcellulose, métabisulfite de sodium, sorbitol liquide (70 %), tampon et, éventuellement, colorant ;
    (i) Composition 9 comprenant une matrice de gel liquide contenant les éléments suivants :
    lidocaïne ; adrénaline ; et
    cétrimide,
    et la composition est éventuellement colorée, dans laquelle ladite composition a un pH inférieur à environ 4,0;
    (j) Composition 10 comprenant une matrice de gel liquide qui contient les éléments suivants : tétracaïne, adrénaline et cétrimide, et la composition est éventuellement colorée, dans laquelle ladite composition a un pH inférieur à environ 4,0; ou
    (k) Composition 11 comprenant une matrice de gel liquide qui contient les éléments suivants : lidocaïne, bupivacaïne, adrénaline et cétrimide, et la composition est éventuellement colorée, dans laquelle ladite composition a un pH inférieur à environ 4,0.
  3. Composition topique destinée à être utilisée selon la revendication 1 ou la revendication 2, dans laquelle la maladie pathogène est l'ecthyma contagieux (Orf).
  4. Composition topique destinée à être utilisée selon la revendication 1 ou la revendication 2, dans laquelle la maladie pathogène est la fièvre aphteuse (FMD).
EP20814805.6A 2019-05-28 2020-05-06 Composition pour utilisation dans le traitement de la fièvre aphteuse, de l'orf, du picornavirus, du parapoxvirus et d'une maladie pathogène provoquant des lésions de la vérole Active EP3976018B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2019901837A AU2019901837A0 (en) 2019-05-28 Further methods of disease control
AU2019901824A AU2019901824A0 (en) 2019-05-28 Method of disease control
PCT/AU2020/050447 WO2020237284A1 (fr) 2019-05-28 2020-05-06 Procédé de lutte contre les maladies

Publications (3)

Publication Number Publication Date
EP3976018A1 EP3976018A1 (fr) 2022-04-06
EP3976018A4 EP3976018A4 (fr) 2023-04-05
EP3976018B1 true EP3976018B1 (fr) 2024-08-28

Family

ID=73552134

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20814805.6A Active EP3976018B1 (fr) 2019-05-28 2020-05-06 Composition pour utilisation dans le traitement de la fièvre aphteuse, de l'orf, du picornavirus, du parapoxvirus et d'une maladie pathogène provoquant des lésions de la vérole

Country Status (11)

Country Link
US (1) US20220226297A1 (fr)
EP (1) EP3976018B1 (fr)
CN (1) CN114040756A (fr)
AU (1) AU2020285360B2 (fr)
CA (1) CA3141886A1 (fr)
CL (1) CL2021003143A1 (fr)
DK (1) DK3976018T3 (fr)
ES (1) ES2991426T3 (fr)
MA (1) MA56067A (fr)
WO (1) WO2020237284A1 (fr)
ZA (1) ZA202110887B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021203856B2 (en) * 2021-06-10 2023-03-09 Animal Ethics Pty Ltd Topical anaesthetic composition having improved vasoconstrictor stability

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4147770A (en) * 1976-12-27 1979-04-03 Scholl, Inc. Preparation for treating dermatitis in the nature of tinea pedis
WO1993000114A1 (fr) * 1991-06-20 1993-01-07 Viro-Tex Corporation Composition a usage local ameliorant la cicatrisation de lesions dues a l'herpes
ES2585654T3 (es) 2005-03-15 2016-10-07 Animal Ethics Pty Ltd Composición anestésica tópica
US8450330B2 (en) * 2007-08-29 2013-05-28 Yung Shin Pharmaceutical Industrial Co., Ltd. Pharmaceutical acceptable composition containing non-steroidal anti-inflammatory drug and local anesthetics
CN101306164B (zh) * 2008-07-14 2010-10-06 张振生 治疗牲畜口蹄疫的中草药
WO2014159731A1 (fr) * 2013-03-13 2014-10-02 Nal Pharmaceuticals, Ltd Composition antivirale topique contenant un anesthésique local et son procédé de fabrication

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Litman's Basics of Pediatric Anesthesia", 1 January 2022, ELSEVIER, ISBN: 978-0-323-82902-1, article KRAEMER F. WICKHAM: "Local Anesthetics and Adjuvant Analgesics", pages: 256 - 259, XP093099575, DOI: 10.1016/B978-0-323-82902-1.00034-2 *
ANONYMOUS: "Local Anesthetics", BASICMEDICAL KEY, 14 August 2016 (2016-08-14), Basicmedical key - Fastest Basicmedical Insight Engine, XP093099732, Retrieved from the Internet <URL:https://basicmedicalkey.com/local-anesthetics-5/> [retrieved on 20231109] *

Also Published As

Publication number Publication date
AU2020285360B2 (en) 2025-01-23
EP3976018A1 (fr) 2022-04-06
DK3976018T3 (da) 2024-09-23
AU2020285360A1 (en) 2021-10-28
CA3141886A1 (fr) 2020-12-03
WO2020237284A1 (fr) 2020-12-03
ES2991426T3 (es) 2024-12-03
ZA202110887B (en) 2024-05-30
EP3976018A4 (fr) 2023-04-05
US20220226297A1 (en) 2022-07-21
MA56067A (fr) 2022-04-06
CN114040756A (zh) 2022-02-11
CL2021003143A1 (es) 2022-09-09

Similar Documents

Publication Publication Date Title
US8960128B2 (en) Topical anesthetic composition
JP7148994B2 (ja) ビスホスホシンゲル製剤及びその使用
RU2414902C1 (ru) Бактерицидная композиция для профилактики и лечения инфекционных заболеваний копыт у животных
US20220072007A1 (en) Compositions and methods for treating an infection
CN105431154A (zh) 抗菌成分
EP2724724B1 (fr) Traitement et prévention des infections épithéliales par des chélates de zinc et de cuivre
US20230015656A1 (en) Compositions and methods for treating an infection
EA005917B1 (ru) Вирулицидные композиции
EP3976018B1 (fr) Composition pour utilisation dans le traitement de la fièvre aphteuse, de l&#39;orf, du picornavirus, du parapoxvirus et d&#39;une maladie pathogène provoquant des lésions de la vérole
US20200352953A1 (en) Compositions and methods for treating an infection
CN100391449C (zh) 氯胺t在治疗皮肤、粘膜、器官和组织之疾病中的应用
WO2011011843A1 (fr) Procédé chimique pour la stérilisation sexuelle et la suppression de la libido chez des mammifères de sexe masculin
TW201513854A (zh) 用於馬的炎症治療之製劑
OA20893A (en) Method of disease control.
RU2764178C1 (ru) Водная бактерицидная композиция для профилактики и/или лечения инфекционных заболеваний копыт у животных и способ ее использования
JP2006501223A (ja) 真菌感染を治療する方法
CN113768908B (zh) 苄丝肼在制备抗动物螨病药物中的应用
AU2007221941B2 (en) A topical anaesthetic composition
Скляров Development of protocols and efficiency of ozone-containing drugs for the treatment of livestock with reproductive pathologies
RU2464988C2 (ru) Средство для лечения мастита у животных на основе тилозина
AU2004101082A4 (en) Anthelmintic compositions
RU2420271C1 (ru) Способ лечения респираторных болезней молодняка сельскохозяйственных животных

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20211202

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
RAV Requested validation state of the european patent: fee paid

Extension state: MA

Effective date: 20211202

A4 Supplementary search report drawn up and despatched

Effective date: 20230306

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 31/12 20060101ALI20230228BHEP

Ipc: A61P 31/10 20060101ALI20230228BHEP

Ipc: A61P 31/04 20060101ALI20230228BHEP

Ipc: A61P 31/02 20060101ALI20230228BHEP

Ipc: A61P 23/02 20060101ALI20230228BHEP

Ipc: A61K 31/14 20060101ALI20230228BHEP

Ipc: A61K 31/245 20060101ALI20230228BHEP

Ipc: A61K 31/167 20060101AFI20230228BHEP

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230526

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20231121

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20240429

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602020036783

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20240919

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2991426

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20241203

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241128

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1717206

Country of ref document: AT

Kind code of ref document: T

Effective date: 20240828

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240828

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241129

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241230

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240828

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240828

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240828

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240828

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240828

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241128

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241128

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241230

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240828

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241128

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240828

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241228

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240828

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241129

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240828

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240828

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240828

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240828

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240828

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240828

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240828

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240828

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240828

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602020036783

Country of ref document: DE

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20250521

Year of fee payment: 6

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20250521

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20250527

Year of fee payment: 6

Ref country code: DK

Payment date: 20250526

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20250521

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20250528

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20250601

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20250521

Year of fee payment: 6

26N No opposition filed

Effective date: 20250530

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240828

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20250630

Year of fee payment: 6